VRTXVERTEX PHARMACEUTICALS INC / MA
Pharmaceutical Preparations
- Revenue
- $12.0B
- 8.9% YoY
- Operating margin
- 34.8%
- 1745% YoY
- EBITDA
- $4.4B
- 17155% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.4×
- −$6.0B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear92% of net incomeCash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear56% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B | 8.9% |
| Operating income | $2.8B | $4.3B | $3.8B | −$233M | $4.2B | 1892% |
| Net income | $2.3B | $3.3B | $3.6B | −$536M | $4.0B | 838% |
| Operating cash flow | $2.6B | $4.1B | $3.5B | −$493M | $3.6B | 837% |
| Capex | $235M | $205M | $200M | $298M | $438M | 47% |
| Stock-based comp | $441M | $491M | $581M | $699M | $686M | 1.8% |
| Buybacks | $1.4B | $0 | $428M | $1.2B | $2.0B | 71% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $932K · 3
- Net
- −$932K
Pay vs performance
No pay-versus-performance disclosure yet.